Albireo

Industry · 11 registered clinical trials.

Status	Trial	Phase	Started
Completed	Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome Alagille Syndrome	Phase 3	2021-03-19
Completed	A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH NAFLD, NASH	Phase 2	2019-06-06
Completed	Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions Healthy Volunteers	Phase 1	2018-07-05
Completed	This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2 PFIC1, PFIC2	Phase 3	2018-05-16
Completed	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Orphan Cholestatic Liver Diseases, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome	Phase 1	2017-01-31
Completed	A4250, an IBAT Inhibitor in Pediatric Cholestasis Pediatric Cholestasis	Phase 2	2015-08-01
Completed	Double-blind, Randomised Study of A3384 in BAM/BAD Bile Acid Malabsorption	Phase 2	2014-03-01
Completed	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis	Phase 1	2013-07-01
Completed	Study of A3309 in Patients With Dyslipidemia Dyslipidemia	Phase 2	2010-02-01
Completed	Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation Constipation, Chronic Constipation	Phase 2	2009-11-01
Approved For Marketing	Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis Progressive Familial Intrahepatic Cholestasis	—	—